Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Gains from Investment Securities (2024 - 2026)

Kestra Medical Technologies (KMTS) reported Gains from Investment Securities of $2.4 million for Q1 2026, up 3330.25% year-over-year from $71400.0 in Q1 2025, and down 46.3% on a QoQ basis from $4.6 million in Q4 2025.

Kestra Medical Technologies (KMTS) has 3 years of Gains from Investment Securities data on file, last reported at $2.4 million in Q1 2026.

  • Quarterly Gains from Investment Securities rose 3330.25% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $2.4 million (up 3330.25% YoY) and the FY2025 annual result came in at $4.6 million, changed N/A from the prior year.
  • Gains from Investment Securities retreated to $2.4 million in Q1 2026 per KMTS's latest filing, from $4.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.6 million in Q4 2025 and bottomed at -$280000.0 in Q3 2025.
  • The 3-year median for Gains from Investment Securities is $206051.0 (2024), against an average of $1.2 million.
  • The widest annual swing landed in 2025, when Gains from Investment Securities plunged 235.89%; it then soared 3330.25% in 2026.
  • Tracing KMTS's Gains from Investment Securities over 3 years: stood at $915548.0 in 2024, then surged by 398.16% to $4.6 million in 2025, then sank by 46.3% to $2.4 million in 2026.
  • Per Business Quant, the three latest KMTS Gains from Investment Securities figures stand at $2.4 million (Q1 2026), $4.6 million (Q4 2025), and -$280000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Kestra Medical Technologies 1.13 Bn 840.05 Mn 12.91 Mn

Historic Data

Download Data 🔒
DateValue
Jan 31, 2026 2.45 Mn
Jan 31, 2026 2.45 Mn
Oct 31, 2025 4.56 Mn
Oct 31, 2025 4.56 Mn
Jul 31, 2025 -280,000.00
Jul 31, 2025 -280,000.00
Apr 30, 2025 2.65 Mn
Apr 30, 2025 2.65 Mn
Jan 31, 2025 71,400.00
Jan 31, 2025 71,400.00
Oct 31, 2024 915,548.00
Oct 31, 2024 915,548.00
Jul 31, 2024 206,051.00
Jul 31, 2024 206,051.00
Apr 30, 2024 -130,000.00
Apr 30, 2024 -130,000.00
Jan 31, 2024 16,200.00
Jan 31, 2024 16,200.00